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Abstract
Background: This is a retrospective cross sectional study aimed to verify whether Multiplex Ligation-dependent
Probe Amplification (MLPA), a quantitative molecular assay, may represent a valuable reflex test in breast cancer
with equivocal HER2 expression by immunohistochemistry and HER2 gene signals/nucleus (s/n) ranging between
4.0 and 5.9 by in situ hybridization.
Methods: A series of 170 breast carcinomas scored as 2+ for HER2 expression by immunohistochemistry, were
selected from our files and analyzed in parallel by silver in situ hybridization and by MLPA. According to ASCO-CAP
2013 guidelines, 54/170 tumors, displaying 4.0–5.9 HER2 gene s/n, were defined as low amplified (ratio ≥ 2) or
equivocal (ratio < 2) on the basis of centromere enumeration probe 17 (CEP17) status. An independent set of 108
score 2+ breast cancers represented the external validation set. Concordance between the two techniques was
assessed through the use of Cohen’s K statistic.
Results: A concordance rate of 78.2% (Cohen’s K statistic: 0,548 95% CI:[0,419–0,677]) between in situ hybridization
and MLPA was found in the whole series of 170 cases and of 55.5% (Cohen’s K statistic: −0,043 95% CI:[−0,271–0,184])
in the 54 tumors presenting 4.0–5.9 HER2 gene s/n. By MLPA, we found HER2 amplification or gain in 14% of the 21 BC
presenting a disomic status and in 18% of the 33 BC presenting a CEP17 > 2.0. These data were further confirmed in
the external validation set. Interestingly, the 54 low amplified/equivocal breast carcinomas presented a frequency of
hormonal receptor positivity significantly higher than that observed in the amplified tumors and similar to the non-
amplified one (p = 0.016 for estrogen receptor and p = 0.001 for progesterone receptor).
Conclusions: To avoid to offer patients an ineffective therapy, HER2 status should be studied more thoroughly in low
amplified and equivocal cases which can have lower response rates and shorter time to progression to trastuzumab. In
this context, our data indicate that MLPA may be a reliable, objective supporting test in selecting HER2 positive breast
cancer patients.
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Background
The introduction of trastuzumab and more recently of
other anti HER2 treatments such as pertuzumab, and
trastuzumab-emtansine (T-DM1) in early-stage and
advanced HER2 positive breast cancer (BC) patients, has
completely changed the natural history of the tumor
both in terms of time to recurrence and survival [1–6].
Nowadays, to correctly identify HER2 positive BC pa-
tients who may benefit from these targeted therapies, is
still a crucial clinical demand. In fact, a false-positive test
could lead to an expensive ineffective treatment associ-
ated with potential side effects. Conversely, a false-
negative test will deprive the patient of an important
therapeutic option [7–9].
Immunohistochemistry (IHC) is the most common
screening test used to detect HER2 protein expression in
BC and may easily identify negative (score 0/1+) and
positive (score 3+) cases whereas IHC 2+ equivocal re-
sults, occurring in up to a quarter of BC, need a reflex
in situ hybridization (ISH) test to identify HER2 positive
cases [10]. Moreover, the last ASCO-CAP guidelines
[11], including incomplete membrane IHC positivity in
the definition of score 2+, yielded an increase in the
number of tumors, which need a reflex ISH test to con-
firm HER2 status [12, 13]. It has been widely reported
that the majority of ISH tests, performed in IHC equivo-
cal cases, may provide unambiguous positive (ratio > 2.0,
average HER2 copy number ≥ 6.0) or negative (ratio < 2.0,
average HER2 copy number < 4.0) results. However, it
has been recently described [14] that approximately 5%
of 2+ BC score present “non classical” HER2 amplifica-
tion due to a ratio or a gene copy number close to the
threshold. According to Ballard [14], the “non classical”
amplified cases include (1) low amplified BC with a ra-
tio ≥ 2.0 and an average HER2 copy number between 4.0
and 5.9, (2) co-amplified BC with a ratio < 2.0, but an
average HER2 copy number ≥ 6.0, (3) monosomy-like
BC with a ratio ≥ 2.0, but an average HER2 copy num-
ber < 4.0, (4) heterogeneous BC presenting clusters of
amplified tumor cells (>10%) associated with clusters of
non amplified tumor cells [11, 14]. This complex
scenario is further complicated by ISH equivocal BC
making up approximately 5% of cases which have an
average HER2 copy number between 4.0 and 5.9, but a
ratio < 2.0. In the latter case the ASCO-CAP guidelines
2013 recommend further HER2 testing on the same or
other tumor samples. Nevertheless, the optimum HER2/
CEP17 ratio cut-off for tumor response in BC patients
treated with trastuzumab both in the (neo)-adjuvant and
metastatic setting is still widely debated [15–19]. In view
of this, novel emerging techniques are described and
aimed to more accurately and more objectively estimate
the HER2 status [20–26]. Although the majority of these
novel techniques demonstrate a good overall correlation
with each other in comparative studies, each assay has
its own advantages and disadvantages and, up to now,
there is neither real gold standard nor validated test to
better define the equivocal subset. In this context, Multi-
plex Ligation-dependent Probe Amplification (MLPA), a
high-throughput PCR-based technique, seems to provide
an alternative valuable and cheap tool to more object-
ively define HER2 status. Aimed to validate its use in
clinical practice, several authors [26–29] compared
MLPA with conventional techniques [30, 31], obtaining
optimal results mainly in clearly amplified and non amp-
lified breast cancer. Conversely, limited MLPA data are
available in the grey zone represented by BC with 4.0–
5.9 HER2 gene s/n. For the purpose of our study, we
evaluated 170 IHC HER2 2+ BC focusing on those cases
showing 4.0–5.9 gene s/n to verify whether MLPA might
be a useful reflex test in low amplified (ratio ≥ 2) and
equivocal (ratio < 2) tumors by ISH. An independent
series of 108 IHC HER2 2+ BC represented the external
validation set.
Methods
Patients
The Pathology Department of the Regina Elena National
Cancer Institute in-house analyzes all the BC with
equivocal IHC results (score 2+) by ISH. Data from our
internal dataset showed that in the last 8 years we found
3066 BC patients presenting a tumor with score 2+ by
IHC. About 11% of the latter series presented 4.0–5.9
HER2 s/n. For the purposes of this retrospective cross
sectional study, 170 BC scoring HER2 2+ by IHC were
selected from our files. Our study comprised also an in-
dependent external set of 108 HER2 2+ BC patients pro-
vided by the Pathology Unit of the University of Turin
(Italy) where all the analyses (IHC, FISH and MLPA)
were performed. The two centers revaluated slides in
order to confirm tumor histologic type, grading, percent-
age of tumor cells and HER2 equivocal expression based
on ASCO-CAP guidelines 2013 in their own cases. Both
centers successfully participated in regional quality con-
trol programs for the IHC assessment of HER2 [32, 33].
The study was reviewed and approved by the Local Ethic
Committee at the Regina Elena National Cancer Insti-
tute and a written informed consent was obtained from
all patients (del. n.180/2014).
Immunohistochemistry
Three-micrometer sections of formalin-fixed paraffin-
embedded breast cancers, were cut on SuperFrost Plus
slides (Menzel-Gläser, Braunschweig, Germany). Estrogen
(ER) and Progesterone (PgR) receptors were analyzed by
using the monoclonal antibodies (MoAbs) 6F11 and 1A6
(Leica Biosystems, Italy) respectively. HER2 and Ki-67
were assessed by using the polyclonal antibody A0485
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(PoAb, Dako, Milan, Italy) and the MoAb MIB-1 (Dako),
respectively. Immunoreactions were revealed by a
streptavidin-biotin enhanced immunoperoxidase tech-
nique (Super SensitiveMultiLink) in an automated auto-
stainer (Bond III, Leica Biosystems). Diaminobenzidine
was used as chromogenic substrate. The external center
used the HercepTest preparation kit (Dako, Glostrup,
Denmark, http://www.dako.com) and scored the results as
previously described [27].
IHC scoring criteria
HER2, hormonal receptor status and proliferation index
(Ki-67) were obtained from the original pathology
reports. In details, HER2 was scored according to the
current guidelines [11]. Thresholds for estrogen receptor
(ER), progesterone receptor (PgR) and Ki-67 prolifera-
tion index were ≥1%, >20% and ≥20, respectively [34].
Dual in situ hybridization assay
To assess HER2 gene and chromosome 17 (CEP17) status
we used a fully automated dual color in situ hybridization
assay based on the use of an automated silver deposition
technology (DDISH, Roche Diagnostic, Monza, Italy). All
reagents included dinitrophenyl (DNP) HER2 and CEP17
probe cocktails. The ultraView SISH and ultraView Alka-
line Phosphatase Red ISH detection kits were used. Slides
were counterstained with hematoxylin and post-
counterstained with a bluing reagent. After removal from
the instrument, slides were rinsed with mild soap tap
water, then rinsed in distilled water, dried at room
temperature, and cover-slipped. The black HER2 SISH
signals and the CEP17 red signals were enumerated in the
tumor nuclei using a bright-field microscopy under a
100X oil immersion objective. After scanning the entire
section, a total of 120 cells was analyzed in at least three
selected fields.
FISH assay
FISH was performed according to the manufacturer’s
instructions with probes for HER2 and CEP17
(Abbott Molecular Diagnostics, Abbott Park, IL,
https://www.abbottmolecular.com), as previously de-
scribed [27, 35].
ISH scoring criteria
According to the current ASCO-CAP guidelines, a BC
displaying a ratio between HER2 gene and CEP17 ≥ 2.0
or with an average of more than or equal to six gene s/n
is considered as amplified. The equivocal and the low
amplified range is defined as HER2/CEP17 ratio < 2.0
and ≥2.0, respectively with an average gene copy number
between 4.0 and 5.9 in both cases. All BC with a
ratio < 2.0 and with an average < 4.0 gene s/n are desig-
nated as negative. An increased CEP17 copy number is
considered to be present when a mean number of
>2.0 s/n is observed in at least 60 tumor cell nuclei.
Multiplex ligation-dependent probe amplification
Multiplex Ligation-dependent Probe Amplification
(MLPA) (MRC-Holland, Amsterdam, The Netherlands) is
a semi quantitative technique which needs only minute
quantities of DNA isolated from paraffin-embedded tis-
sues. Both participating centers performed MLPA as
follows: invasive tumor areas as identified on serial
haematoxylin/eosin (H&E) sections by a pathologist were
harvested from 3 or 4 whole 5 μm thick paraffin sections
by macrodissection. DNA was isolated using the QIAamp
DNA kit (QIAGEN, Milan, Italy) according to the manu-
facturers’ instructions. This DNA solution, after centrifu-
gation and quantification with NanoDrop TM 1000
spectrophotometer (ThermoScientific Fisher, Wilmington,
DE, USA), was used in the MLPA. The P004-C1 ERBB2
kit (MRCHolland, Amsterdam, The Netherlands) contains
4 probes recognizing different sequences of the HER2
gene, and 27 probes for other genes on Chr17. In addition,
6 probes targeting genes on other chromosomes are in-
cluded. Also the kit contains twelve reference probes spe-
cific for chromosomal regions, which have been found to
be silent regions in CGH experiments. Briefly, 150–200 ng
of target DNA per 5 μl of 10 mM pH 8.3 Tris-HCl
0.1 mM EDTA was denatured for 5 min at 98 °C after
which 3 μl of the hemiprobe mix was added. The mixture
was heated at 95 °C for 1 min and incubated at 60 °C over-
night (16–20 h). After hybridization to the target
sequences, the hemiprobes were ligated and then ampli-
fied. Ligation was performed with the temperature stable
Ligase-65 enzyme (MRC-Holland) for 15 min at 54 °C.
Next, the ligase was inactivated by heat in the thermocy-
cler for 5 min at 98 °C and then paused at 20 °C. PCR was
carried out for 35 cycles (30 s at 95 °C, 30 s at 60 °C, and
1 min at 72 °C). All tests were performed in duplicate on
an Applied Biosystems® Veriti®Thermal Cycler. A variable
stuffer sequence on one of the hemiprobes determined
the length of the PCR product of each gene. The frag-
ments obtained were analyzed with an ABI model 3130
capillary sequencer (Life technologies, Monza, Italy) using
GeneScan™ 500 LIZ™ dye Size Standard (Life technologies,
Warrington, UK).
Final results were calculated using dedicated software
(Coffalyser.NET). The comparison with reference DNA
samples derived from healthy individuals is essential in
obtaining an accurate final result. To this end three
negative reference samples (normal breast) were taken
along in each MLPA run to normalize MLPA ratios. For
genes with more than one probe present in the kit, the
mean of all the probe peaks of this gene in duplicate was
calculated. Mean values <0.7 refer to gene deletion, be-
tween 0.7–1.3 to normal gene status and values between
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1.3–1.5 and >1.5 to gains and gene amplification re-
spectively. These cut-off were validated in breast cancer
cell lines showing HER2 amplification (BT474: 6 HER2
copy number by FISH, MLPA ratio of 5), HER2 gain
(T47D: 4 HER2 copy number by FISH, MLPA ratio of
1.32) and lacking HER2 gain or amplification (MCF7: 2
HER2 copy number by FISH, MLPA ratio of 0.61).
Statistical analysis
All variables of interest were summarized through fre-
quencies and percentage values. Concordance between
the two techniques was assessed through the use of
Cohen’s K statistic (K) [36]. Each K value was reported
with its relative 95% Confidence interval (95% CI) and
interpreted in a qualitative manner based on the Landis
and Koch classification criteria [37].
Results
Patient characteristics
According to the World Health Organization classification
[38] out of the 170 BC with HER2 score 2+ by IHC in-
cluded in the study, 161 were infiltrating carcinomas of no
special type, 4 invasive lobular carcinomas and 5 special
histologic types. As summarized in Table 1, 12 (7%)
tumors were graded, using the Elston and Ellis scoring
system [39], as well differentiated (G1), 76 (45%) and 82
(48%) as moderately (G2) and poorly differentiated (G3)
carcinomas, respectively. ER and/or PgR were positive in
132 (78%) BC and Ki67 was high in 97 (57%) cases. Out of
the 170 BC analyzed by DDISH, 61 (36%) presented a
HER2 s/n < 4.0, 54 (32%) between 4.0–5.9 s/n and 55
(32%) ≥6.0 s/n. Of the 108 score 2+ BC, belonging to the
external validation set, 92 were infiltrating carcinomas of
no special types, 8 invasive lobular carcinomas and 8 were
special histologic types. Seventeen (16%) tumors were
graded as well differentiated (G1), 55 (51%) and 26 (24%)
as moderately (G2) and poorly differentiated (G3) carcin-
omas, respectively. ER and/or PgR were positive in 99
(92%) BC and Ki67 was high in 52 (48%) cases. FISH evi-
denced 80 (74%) BC with <4.0 HER2 s/n, 10 (9%) with
4.0–5.9 HER2 s/n and 18 (17%) with HER2 ≥ 6.0 s/n.
Concordance between ISH and MLPA results in the
internal and in the validation set
A concordance rate of 78.2% (Table 2, Cohen’s K statis-
tic: 0.548 95% CI [0.419–0.677]) between ISH and MLPA
was found in the whole series of 170 cases. Overlapping
results were found in the external set of 108 BC where
the concordance rate was 76.9% (Cohen’s K statistic:
0.464 95% CI [0.280–0.648]). In each series, the con-
cordance value between the two techniques, showed a
moderate agreement (0.41 < k < 0.60) following the Lan-
dis and Koch criteria. To understand which variables
may affect this agreement, we subdivided our series and
the external validation series into 2 separate groups as
follow: (1) 61 and 79 clearly non amplified BC (<4.0
HER2 s/n) as well as 55 and 19 highly amplified BC
(≥6.0 HER2 s/n). (2) 54 and 10 BC presenting an equivo-
cal number of gene s/n (4.0–5.9 HER2 s/n).
Table 1 Biopathological characteristics of the two breast cancer sets
Internal set External set
Total number of patients 170 108
Grading
1 12 (7%) 17 (16%)
2 76 (45%) 55 (51%)
3 82 (48%) 26 (24%)
unknown 0 (0%) 10 (9%)
Node
Negative 67 (39%) 55 (51%)
Positive 77 (46%) 38 (35%)
unknown 26 (15%) 15 (14%)
HR Status
ER and/or PgR positive 132 (78%) 99 (92%)
ER /PgR negative 38 (22%) 9 (8%)
Ki67
High ≥20% 97 (57%) 52 (48%)
Low < 20% 73 (43%) 56 (52%)
HER2 gene s/n
<4.0 61a (36%) 80b(74%)
4.0–5.9 54a(32%) 10b (9%)
≥6.0 55a (32%) 18b(17%)
HR Hormonal Receptor, ER Estrogen Receptor,PgR Progesterone Receptor,
s/n signals/nucleus
aSilver In Situ Hybridization; bFluorescence In Situ Hybridization
Table 2 Concordance between ISH and MLPA in the internal and
external validation set
DDISH (N = 170)* Cohen’s K Statistic [95% CI]
NA A
94 76
MLPA 0.548 [0.419–0.677]
NA 86 29
A 8 47
FISH (N = 108)**
NA A
87 21
MLPA 0.464 [0.280–0.648]
NA 64 2
A 23 19
NA Non Amplified, A Amplified, MLPA A = Amplified + Gain
* Internal set ** External set
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First group analyses
Table 3 summarizes the concordance between ISH and
MLPA both in the non amplified (NA) and amplified (A)
cases in our series and in the external validation set. In
our series, we found that of the 61 HER2 NA cases by
DDISH, 59 (97%) were also non amplified by MLPA
(Fig. 1a, b). Among the 55 HER2 amplified BC by
DDISH, MLPA confirmed HER2 gene amplification in
41 cases (75%) (Fig. 1c, d). In contrast, 11 tumors (20%)
had a normal HER2 gene status and 3 (5%) presented a
HER2 gene gain. A concordance rate between DDISH
and MLPA of 88,8% (Cohen’s K statistic: 0,773 95%
CI:[0,594–0,953]) was found. Following Landis and Koch
criteria, this value showed a substantial agreement
(0.61 < k < 0.80) between the two techniques. Concern-
ing the external validation set, among the 79 NA cases,
MLPA confirmed the lack of amplification in 62 tumors
(79%). In the remaining 17 BC, 7 (9%) presented a HER2
gain and 10 (12%) were amplified. Among the 19 HER2
amplified BC by FISH, MLPA confirmed HER2 gene
amplification in 15 tumors (79%), 2 (10.5%) had a nor-
mal HER2 gene status and 2 (10.5%) presented a gain.
The concordance rate between FISH and MLPA was of
80.6%, Cohen’s K statistic: 0.523 95% CI:[0,339–0,706].
Following the Landis and Koch criteria, this value shows
a moderate agreement (0.41 < k < 0.60) between the two
techniques.
Second group analyses
As summarized in Table 4, we focused on the 54 BC
with 4.0–5.9 HER2 s/n belonging to our series and we
found that 21 (39%) cases presented a normal CEP17
status and 33 (61%) had an increased CEP17 s/n by
DDISH. According to the 2013 ASCO-CAP, the 21 di-
somic BC could be considered amplified (ratio ≥ 2.0),
whereas the 33 BC presenting an altered CEP17 status
(>2.0 s/n) were equivocal and need a reflex test to defin-
itely establish HER2 status. MLPA is a method capable
of highlighting, beyond HER2, also alterations of CEP17
genes including WSB1 and NOS2A loci which are closed
to the centromeric region. Out of the 21 BC presenting
2 CEP17 s/n, 1 (5%) was HER2 amplified (mean value
≥1.5) by MLPA, 2 (9%) showed a gain (mean value ≥1.3
but <1.5), the other 18 resulted HER2 non amplified
(mean value <1.3). Among the 33 equivocal cases due to
an altered CEP17 status by DDISH, MLPA found 4
(12%) HER2 amplified BC (mean value ≥1.5, Fig. 2), 2
(6%) with a gain (mean value ≥1.3, but <1.5) and the
remaining 27 non amplified (mean value <1.3) In the lat-
ter cases, we found a 55,5% concordance rate between
DDISH and MLPA (Cohen’s K statistic: -0.043,
95%CI:[−0,271–0,184]). Therefore, no agreement was
observed.
In the external validation series, out of the 10 BC with
4.0–5.9 HER2 s/n by FISH, 2 presented a disomic pat-
tern of which, through MLPA, 1 (50%) was amplified
(mean value ≥1.5) and 1 (50%) showed a gain (mean
value ≥1.3 but <1.5). Among the 8 cases presenting an
altered CEP17 status (>2.0), MLPA found 4 BC (50%)
HER2 amplified (mean value ≥1.5), 2 (25%) with a gain
(mean value ≥1.3 but <1.5) and the other 2 (25%) non
amplified (mean value <1.3). The concordance rate be-
tween FISH and MLPA was 40% (Cohen’s K statistic:
0,118 95%CI:[−0,174–0,409]). Following the Landis and
Koch criteria, this value shows only a slight agreement
(0.01 < k < 0.20) between the two techniques. We found
amplification or gain of WSB1 and/or NOS2A in 16/33
cases (48.5%) of our series (data not shown) and in 5/8
(62.5%) cases of the external validation series.
Association between HER2 gene copy number and
immunophenotypical factors in the 54 low amplified and
equivocal breast cancers
We explored the potential association between the
HER2 gene copy number (<4.0, between 4.0–5.9, ≥6.0)
and immunophenotypical factors ER, PgR and Ki67 in
the entire cohort of 278 BC. Figure 3 shows that BC pre-
senting a low amplification rate (4.0–5.9 HER2 s/n,
CEP17 = 2.0) have a significantly higher percentage of
ER (p = 0.016) and/or PgR positivity (p = 0.001) and a
lower percentage of Ki67 proliferation index (p = 0.027)
than highly amplified tumors (>6.0 HER2 s/n). In par-
ticular, BC with 4.0–5.9 HER2 gene s/n show an immu-
nophenotypical profile more similar to the HER2 non
amplified BC than amplified BC (p = 0.260, p = 0.257,
p = 0.947) (data not shown).
Discussion
Our Pathology Department analyzes HER2 status in
more than 1000 BC per year. In particular, between 2009
and 2016, 3066 consecutive cases showed IHC HER2
equivocal status (score 2+) and underwent ISH analysis
to definitely identify HER2 positive BC. Even though in
Table 3 ISH and MLPA results in High Amplified/Non Amplified
breast cancers in the internal and external validation set
DDISH (N = 116)a FISH (N = 98)b
gene s/n gene s/n
<4.0 ≥6.0 <4.0 ≥6.0
61 55 79 19
MLPA
NA 59 (97%) 11 (20%) 62 (79%) 2 (10.5%)
GAIN 0 (0%) 3 (5%) 7 (9%) 2 (10.5%)
A 2 (3%) 41 (75%) 10 (12%) 15 (79%)
NA Non Amplified, A Amplified, NA < 1.3 mean value, GAIN ≥ 1.3 < 1.5 mean
value, A ≥ 1.5 mean value
aInternal set bExternal set
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the majority of cases, ISH testing is able to accurately
discriminate amplified from non-amplified tumors, 11%
of our BC routine series presented a mean of HER2 gene
s/n ranging between 4.0 and 5.9. According to the 2013
ASCO-CAP guidelines [11], 8% were amplified due to a
HER2/CEP17 ratio ≥ 2.0 and 3% were equivocal since
CEP17 signals produced a ratio < 2.0. The two categor-
ies, low amplified and equivocal, as highlighted in our
routine series, are in line with those reported by Ballard
et al. [14] in a recent and elegant study concerning the
non classical HER2 FISH results. It is of paramount clin-
ical importance to carefully define the HER2 status in
these uncommon subsets of BC in which the mean
CEP17 copy number drives in the final classification
based on the ISH algorithm proposed by the guidelines.
To this end, we evaluated whether MLPA, a quantitative
molecular method [26, 28, 29, 40] may be a helpful re-
flex test to define the HER2 status in 54 BC presenting a
non classical HER2 ISH results (4.0–5.9 HER2 gene s/n).
One hundred and sixteen BC including 55 HER2 clearly
Fig. 1 MLPA and DDISH in HER2 non amplified and amplified breast carcinomas. Two exemplificative BC a-d showing respectively a HER2 normal
gene status a by MLPA (mean value 0.82) and b by DDISH (ratio < 2.0) and HER2 gene amplification c by MLPA (mean value 8.45) and d by
DDISH (>6.0 s/n, ratio ≥ 2.0). Scale bar = 30 μm
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amplified (>6.0 gene s/n) and 61 clearly non amplified
(less than 4.0 gene s/n, ratio < 2.0) BC represented our
control series. Moreover, an independent set of 108 IHC
2+ BC, of which 10 had a non classical HER2 gene pat-
tern, represented our external validation set. Several
studies already demonstrated that MLPA is an easy
method to perform and interpret HER2 status with a
good correlation with IHC and ISH [28–31]. Neverthe-
less, to the best of our knowledge, this is the first study
which investigated whether MLPA may provide useful
diagnostic information in two independent BC series
presenting a mean of 4.0–5.9 HER2 genes/n which can
be often difficult to define as amplified or not. The
concordance rate between DDISH and MLPA obtained
in this series of 54 BC was 55.5%, a percentage
significantly lower than that obtained in the 116 BC
made up by clearly amplified and non amplified BC
(concordance 88.8%). This observation further indicates
the peculiar biological characteristics of these low ampli-
fied or equivocal cases. As already reported by Ballard
[14], we observed, in fact, that tumors harboring 4.0–5.9
HER2 gene s/n had a frequency of ER positivity similar
to the non amplified category. These data were
confirmed in the external validation set supporting the
recommendation to consider all the clinico-pathological
features on a case-by-case basis when planning HER2-
targeted therapies in these critical cases. Several recent
studies which compared MLPA and ISH techniques,
were broadly concordant with our results. The data re-
ported so far have demonstrated that there are specific
scenarios in which MLPA may be of particular value in
HER2 testing when selecting patients to undergo anti
HER2 treatment [26–28, 40]. In this context, BC pa-
tients displaying a mean of the HER2 gene s/n ranging
between 4.0–5.9, including both low amplified and
equivocal tumors, could benefit most from MLPA. We
have previously reported a small cohort of HER2 equivo-
cal BC where 75% presented a normal HER2 status
whereas 25% showed HER2 gain [27]. Here we now re-
port data on a series of 54 low amplified and equivocal
cases where MLPA uncovers HER2 amplification in
about 17% of cases and seems to be an optimal reflex
test mainly in the group of 33 cases defined equivocal by
DDISH. The external validation series had a strikingly
similar frequency. Whether patients with HER2 equivo-
cal tumors should receive targeted therapy remains a
challenging question for oncologists, particularly as
reporting guidelines evolve. The 2007 ASCO-CAP
guidelines [41] did not recommend anti HER2 treatment
for patients with an equivocal test. On the other hand,
the 2013 ASCO/CAP guidelines [11] opened the possi-
bility to oncologists to consider HER2-targeted therapy
also for patients with equivocal HER2 test results, even
after reflex testing with an alternative assay. Clearly,
there is a need to further examine this critical subset of
tumors, whose relative frequency has increased following
the application of the 2013 ASCO-CAP guidelines [11].
A recent re-evaluation of HERA trial FISH results ac-
cording to the 2013 ASCO-CAP guidelines on 6018 BC,
showed an increase of equivocal cases from 0.7% to 1.9%
[9]. In another recent study [42], the authors reviewed a
Fig. 2 An equivocal HER2 breast cancer by DDISH and MLPA. An exemplificative case of breast cancer HER2 equivocal a by DDISH (gene s/n of
5.2 and CEP17 > 2.0) and b amplified by MLPA (mean value of 2.2). The tumor presents a co-amplification of the CEP17 gene WSB1 (mean value 2.3).
Scale bar = 30 μm
Table 4 ISH and MLPA results in low amplified and equivocal
breast cancers in the internal and external set
DDISH (N = 54)a FISH (N = 10)b
4.0–5.9/=2 4.0–5.9/>2 4.0–5.9/=2 4.0–5.9/>2
21 33 2 8
MLPA
NA 18 (86%) 27 (82%) 0 (0%) 2 (25%)
GAIN 2 (9%) 2 (6%) 1 (50%) 2 (25%)
A 1 (5%) 4 (12%) 1 (50%) 4 (50%)
NA Non Amplified, A Amplified, NA < 1.3 mean value, GAIN ≥1.3 < 1.5 mean
value, A ≥ 1.5 mean value
aInternal set: gene /CEP17 s/n bExternal set: gene /CEP17 s/n
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consecutive series of 904 BC observing a switch from
HER2 FISH negative in HER2 FISH equivocal in 7,3% of
cases. The majority of these reclassified cases presented
a gained CEP17. The lack of an overall agreement be-
tween ISH and MLPA assays, mainly in tumors with
4.0–5.9 HER2 gene s/n, is due to both genetic hetero-
geneity and tumor cellularity of the sample [27]. In line
with other authors [28], we observed that the best
correlation between the two techniques is found when
there is more than 30% of cancer cells in the test sample.
Therefore, in order to eliminate any potential bias in our
results due to low tumor cell percentage, the 170 BC in-
cluded in the present study had to have at least 30% of
tumor cells in the entire section. Furthermore, a tumor
macrodissection was performed before MLPA testing.
All cases belonging to the second group of 54 BC had
the same range of mean HER2 gene s/n (4.0–5.9), but
varied in the mean CEP17 s/n. According to 2013
ASCO-CAP, all the disomic tumors were HER2 ampli-
fied by ISH whereas MLPA found HER2 amplification or
gain in 14% of the latter cases. In the group of equivocal
tumors MLPA may objectively identify HER2 amplifica-
tion in 18% of BC. This data raises the question whether
the lack of amplification by MLPA is due to a bias
induced by the method itself or vice-versa MLPA was
able to exactly identify only the fraction of the true
amplified cases. Concerning the first issue, the lack of
amplification by MLPA may be due to intermixed gen-
etic heterogeneity, an important biological mechanism
that correlates with a low level of amplification and
equivocal HER2 status. Lee et al. [43] analyzed 443
HER2 positive BC and found HER2 regional and gen-
etic heterogeneity in 6.2% and 6.8%, respectively.
These authors demonstrated that both types of het-
erogeneity were significantly associated with low levels
of HER2 gene amplification. The objective results
provided by MLPA in identifying the HER2 status
may be of particular clinical importance. Recent
studies indicated, in fact, that patients with overall
low-level or equivocal HER2 amplification had signifi-
cantly lower response rate to neo-adjuvant trastuzu-
mab [44] and shorter time to progression and overall
survival in metastatic BC treated with trastuzumab
based chemotherapy than did those with high-level
amplification [18, 19]. Qian et al. [45] compared the
HER2 FISH status based on the 2007 and 2013
ASCO/CAP guidelines in 1931 BC cases. The authors
noted that the last guidelines, although improving the
identification of amplified cases, provided an increase
in the equivocal cases. Furthermore, the observation
that FISH equivocal cases do not always reflect HER2
overexpression might suggest the growing need to
carefully select patients who can benefit from HER2
targeted treatment. These concerns were widely de-
bated during the 15th St Gallen International Breast
Cancer Conference [46]. A randomised phase III trial,
NSABP B47 is ongoing and will probably elucidate
the best treatment approach for these patients.
Fig. 3 Association between HER2 s/n and immunophenotypical factors. The 64 breast carcinomas presenting 4.0–5.9 HER2 s/n included in our study
have a significantly higher percentage of estrogen (p = 0.016) and/or progesterone (p = 0.001) positivity, and a lower percentage of Ki67 proliferation
index (p = 0.027) than highly amplified tumors (≥6.0 HER2 s/n)
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Conclusions
In this study we confirmed that MLPA is a valuable and
reproducible method to identify HER2 status in clearly
non amplified or high amplified breast carcinomas.
Nevertheless, the benefit of HER2-targeted therapies for
BC patients presenting an equivocal/low level HER2 sta-
tus are currently unknown, as assessed by the panelists
partecipating to the 15th St Gallen International Breast
Cancer Conference. These observations strengthen the
concept that HER2 status should be studied more thor-
oughly in low amplified and equivocal cases avoiding to
offer patients an ineffective therapy. In this context, our
data indicate that MLPA could be an alternative, object-
ive supporting test in selecting HER2 positive breast
cancer patients. Nevertheless, our data should be consid-
ered as preliminary results to be further validate on a
larger and prospective number of cases.
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